Moderna stock: Buy the dip?

The stock is down 9% after a valuation downgrade from Bank of America.

| More on:
A trader stand looking at a sharemarket graph emblazoned with the words buy and sell

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Moderna Inc (NASDAQ: MRNA) stock is down 9% on Monday after Bank of America analyst Geoff Meacham downgraded his opinion on the stock from neutral to underperform and kept his $150 target on the shares. Moderna, which traded hands at $185 on Friday, opened at $173 and dropped down to $154 in early trading.

The biotech stock skyrocketed in 2020 because of the COVID-19 pandemic, running up from $19 a share to $111. Moderna's messenger RNA (mRNA) platform allows it to find vaccines quickly and get them into clinical trials before its rivals.

Meanwhile, Pfizer signed a collaboration agreement with another biotech, BioNTech, another mRNA specialist, to develop its COVID-19 vaccine. Moderna and Pfizer were neck-and-neck all year in the race to get COVID-19 vaccines to the public. The Food and Drug Administration (FDA) granted emergency-use authorisation to both companies in December.

Moderna has a wide-ranging platform with 27 molecules in its pipeline, so long-term investors could be rewarded if it finds success in any major programs including vaccines for cytomegalovirus and certain cancers.

While the market was already bullish about Moderna prior to the pandemic, the huge run-up in valuation is undoubtedly due to its ability to produce (and get clearance) for a highly effective COVID-19 vaccine in under a year. Moderna's phase 3 data and the FDA's resulting decision is seen as a proof-of-concept for Moderna's mRNA platform. Moderna expects to bring in $11 billion in revenue from its vaccine this year.

However, there is a serious downside to Moderna's vaccine and the class of mRNA vaccines in general: distribution issues. Pfizer's drug has to be frozen, and Moderna's vaccine has a 30-day window before it starts to go bad. As a consequence, other vaccine makers like Johnson & Johnson and Novavax might end up taking a larger market share if and when they cross the regulatory finish line, and that could put downward pressure on Moderna's stock.

Investors should probably wait for a cheaper price to buy Moderna.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Taylor Carmichael owns shares of Novavax. The Motley Fool Australia's parent company Motley Fool Holdings Inc. recommends Johnson & Johnson and Moderna Inc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on International Stock News

Virtual goggles
International Stock News

Here are 2 safe Metaverse stocks for risk-averse investors

These tech companies could benefit in a big way from the creation of the metaverse, but they're already highly profitable…

Read more »

Electric vehicle being charged.
International Stock News

Tesla shareholders approved a 3-for-1 stock split — is the stock a buy?

Tesla's share price has climbed 77% since its last stock split in August 2020.

Read more »

A graphic of a non-fungible token
International Stock News

This NFT-linked cryptocurrency just surged into a top-30 spot

Judging by Flow's price action of late, the NFT space could be one to watch right now.

Read more »

The word cryptocurrency on a round clock.
International Stock News

Why Polkadot, Solana, and Cardano are 3 altcoins in focus today

Investors appear to be increasingly focused on fundamental growth metrics in the crypto world.

Read more »

A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
International Stock News

Why US growth stocks jumped today

The market is back in "risk-on" mode.

Read more »

The word crypto spelt out in front of a blue background.
International Stock News

Why Bitcoin, Ethereum, and Dogecoin are shooting higher today

Top cryptocurrencies are starting the week off with a bang as investors take a bullish view of these risk assets.

Read more »

happy family playing video game
International Stock News

Why GameStop stock is gaining today

Another meme-stock rally pushed the video game retailer higher.

Read more »

woman with coffee on phone with Tesla
International Stock News

Here’s why Tesla stock popped today

Investors had two bits of good news today.

Read more »